Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 28 of 34.
Jan 2012
Dec 2011
16 Dec · Disclosure
Compensation Committee of Directors of the Company at its meeting held on December 16, 2011, has considered and approved grant of 12,05,000 options at an exercise price of Rs.91.60 per option (each option confer a right to one equity share of Re.1/- each) under the Employees Stock Option Plan, 2006.
Nov 2011
28 Nov · Updates
Vide its letter dated November 28, 2011, that "There was a fire incident in a powder processing area at early hours today at Unit 11, which is located at Pydibhimavaram, Srikakulam near Vizag, A.P. Three persons were injured and they were taken to the hospital. The powder processing area is isolated from the intermediate block. There was no impact to the operations as well as to the assets".8 Nov · Results
Consolidated Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 107530 lacs for quarter ending on 30-SEP-2011 against Rs. 111262 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. (8016) lacs for the quarter ending on 30-SEP-2011 against Rs. 19832 lacs for the quarter ending on 30-SEP-2010.8 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 95769 lacs for quarter ending on 30-SEP-2011 against Rs. 105043 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. (4188) lacs for the quarter ending on 30-SEP-2011 against Rs. 21403 lacs for the quarter ending on 30-SEP-2010.
Oct 2011
31 Oct · Board meeting
To consider inter alia, the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2011.
Sep 2011
Aug 2011
22 Aug · Updates
Company or any of its subsidiaries do not have investments in M/s. Jagathi Publications Private Limited or in any of its Associate Companies.
Jul 2011
30 Jul · Meeting
27 Jul · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2011.
Jun 2011
May 2011